



OPPI News Update: February 28, 2014

Patents/Compulsory Licensing/Intellectual Property

Publication: The Financial Express

Edition: National

Date: February 28, 2014

Opinion piece: DG Shah, CEO of Vision Consulting Group, a firm specialising in strategic planning

Headline: [‘Can’t buy American stories’](#)

Synopsis: DG Shah highlights that US trade bodies’ campaign against India defies logic as American firms are flourishing here. He spoke about US companies working relentlessly to launch an investigation by the US International Trade Commission (ITC) against India’s ‘unfriendly’ business environment. The focus was on IP protection and enforcement in health care, information, communication and entertainment (HICE) sectors. Some of the trade associations such as National Association of Manufacturers, Alliance for Free Trade with India, Global Intellectual Property Center, etc. have already pronounced their ‘guilty’ verdict for India even before the ITC hearing is over!

Publication: The Financial Express

Edition: National

Date: February 28, 2014

Headline: [U.S. high court sets record for intellectual property caseload](#)

Synopsis: In a sign of the growing struggles that judges face applying old laws to new technology, the U.S. Supreme Court this year is hearing the highest proportion of intellectual property cases in its history. In the court's nine-month term ending in June, the justices will decide eight cases on intellectual property issues: six on patent law, two of which were argued on Wednesday, and two on copyright law.

FDA

Publication: The Financial Express

Edition: National

Date: February 28, 2014

Headline: FDA failed to track sub-standard generics, experts tell US Congress (link unavailable, scan attached)

Synopsis: The Food and Drug Administration has failed to monitor the effectiveness of generics that make up 80% of medicines sold in the US, according to doctors and researchers who said new regulatory efforts aren't enough. Generic heart drugs made by some India-based companies don't work as they should, said Preston Mason, a researcher at Brigham & Women's Hospital in Boston who has studied the effectiveness of copies of Pfizer's Lipitor made in the US and abroad. That may be because some companies are cutting corners to save money, he said.

Similar report in-

Mint- [Substandard generic drugs slip past US FDA effort, doctors say](#)

Publication: The Times Of India

Edition: National

Date: February 28, 2014

Headline: [FDA officials crack the whip on medical shops sans pharmacist](#)

Synopsis: Continuing to hammer the medical shops that are operational without the appointment of an authorized pharmacist, the Food and Drug Administration (FDA) from April 2013 to January 2014 has cancelled license of nearly 1121 medical stores in Konkan region of its jurisdiction. The Konkan region includes Thane, Raigad, Ratnagiri and Sindhudurg. The FDA wants to ensure strict compliance of the rules, as sale of scheduled drugs without the supervision of a pharmacist is not allowed under the Drugs and Cosmetics Act, 1940.

General Industry

Publication: The Times Of India

Edition: Online

Date: February 27, 2014

Headline: ['India needs an Intellectual Property Rights friendly culture'](#)

Synopsis: Microsoft (India) has established the Intellectual Property Rights (IPR) chair at Gujarat National Law University (GNLU) about which the software giant had made an announcement recently. In an effort to raise awareness about IPR laws in India, Microsoft and GNLU will collaborate on research in the field and organize seminars on IPR for the next five years.